Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial
ConclusionsThe adverse events of mFOLFOX6-bevacizumab or CapeOX-bevacizumab in combination with ip PTX were considered similar to those described in previous studies of oxaliplatin-based treatment alone. 1 year after the start of chemotherapy, the efficacy of ip PTX will be evaluated as a secondary outcome.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Colorectal Cancer | Drugs & Pharmacology | Eloxatin | Gastric (Stomach) Cancer | Gastroenterology | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Peritoneal Cancer | Study | Toxicology | Vitamin B9 | Xeloda